Clinical Trial Update: Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease [Phase 3]

View source ↗

Summary

This is a completed Phase 3 safety and tolerability trial of extended-release galantamine in Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Razadyne ER (galantamine)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED